US Congress Senate Bill 102 (Prior Session Legislation)

---

Spectrum: Moderate Partisan Bill (Democrat 6-1)
Status: Introduced on January 10 2019 - 25% progression, died in committee
Action: 2019-01-10 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]

Establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Prescription Drug Price Relief Act of 2019

Sen. Bernard Sanders [I-VT]	Sen. Cory Booker [D-NJ]	Sen. Richard Blumenthal [D-CT]	Sen. Kirsten Gillibrand [D-NY]
Sen. Kamala Harris [D-CA]	Sen. Elizabeth Warren [D-MA]	Sen. Amy Klobuchar [D-MN]

Date	Chamber	Action
2019-01-10	Senate	Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

HB465 (Same As) 2019-01-25 - Referred to the Subcommittee on Health.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/senate-bill/102/all-info
Text	https://www.congress.gov/116/bills/s102/BILLS-116s102is.pdf